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Insulin-like growth factor 1 (IGF1) is a polypeptide hormone structurally similar to
insulin. It is central to the somatotropic axis, acting downstream of growth hormone
(GH). It activates both the mitogen-activated protein (MAP) kinase and PI3K signaling
pathways, acting in almost every tissue in the body to promote tissue growth and
maturation through upregulation of anabolic processes. Overall GH and IGF1 signaling
falls with age, suggesting that it is this reduced IGF1 activity that leads to age-related
changes in organisms. However, mutations that reduce IGF1-signaling activity can
dramatically extend the lifespan of organisms. Therefore, the role of IGF1 in the
overall aging process is unclear. This review article will focus on the role of IGF1 in
brain development and aging. The evidence points towards a role for IGF1 in
neurodevelopment both prenatally and in the early post-natal period, and in plasticity
and remodeling throughout life. This review article will then discuss the hallmarks
of aging and cognitive decline associated with falls in IGF1 levels towards the
end of life. Finally, the role of IGF1 will be discussed within the context of both
neuropsychiatric disorders caused by impaired development of the nervous system,
and neurodegenerative disorders associated with aging. IGF1 and its derivatives are
shown to improve the symptoms of certain neuropsychiatric disorders caused by
deranged neurodevelopment and these effects have been correlated with changes in
the underlying biology in both in vitro and in vivo studies. On the other hand, studies
looking at IGF1 in neurodegenerative diseases have been conflicting, supporting both a
role for increased and decreased IGF1 signaling in the underlying pathogenesis of these
diseases.
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Insulin-like growth factor 1 (IGF1) signaling is an essential factor for early brain development,
but its role in the aging brain remains unclear. In fact, while reduced IGF1 signaling with age
has been historically observed as a causative factor in the aging process, correlation does not
imply causation, and falling IGF1 signaling with age may in fact attenuate the effects of aging.
Further work must be done in order to truly discern the role and effects of IGF1 signaling in the
aging brain.
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IGF-1 is synthesized primarily in the liver, where its synthesis
is regulated by pituitary secretion of growth hormone (GH).
It is central to the somatrotropic axis, acting downstream
of GH to promote anabolic processes and tissue growth
throughout life. IGF1 is also synthesized locally in many
organs, including the brain. Both in circulation and in
tissues, IGF1 is bound to high affinity IGF1-binding proteins
(IGFBPs), which modulate interactions between IGF1 and its
receptor.
The biological actions of IGF1 are mediated through IGF1R,
a membrane-bound receptor tyrosine kinase (RTK). Binding
of IGF1 to its receptor causes autophosphorylation of the
intracellular component, leading to enzymatic activation and
subsequent phopshorylation of the insulin receptor substrate-1
(IRS1) protein on multiple tyrosine sites. These phosphotyrosine
sites then serve as docking sites for numerous intracellular
signaling proteins. By bringing these interacting proteins
together, complex signaling pathways are begun, including
the canonical PI3-kinase and mitogen-activated protein (MAP)
kinase pathways.
IGF-1R activation triggers the PI3kinase-Akt signaling
pathway, which promotes cell growth and maturation.
IRS1 binds PI3kinase which phosphorylates PIP2 to PIP3.
PIP3 binds two protein kinases; Akt and PDK1, leading to
activation of Akt, which acts on numerous proteins throughout
the cell to promote cell growth and survival. Downstream
substrates of Akt include mammalian target of rapamycin
(mTOR), which stimulates ribosome production and protein
synthesis, and Bad, a pro-apoptopic protein that is inhibited
by Akt phosphorylation. Another effect of IGF1R activation
through PI3kinase-Akt signaling is inhibitory phosphorylation
of pro-apoptopic glycogen synthase 3β (GSK3β), which is
associated with increased glycogen storage in projection
neurons in the post-natal brain, as well as reduced tau
hyperphosphorylation which causes neuronal death (Bondy
and Cheng, 2004). IGF1-induced PI3K-Akt signaling is
also linked to production of GLUT4 glucose transporters
and translocation to neuronal cell membranes, promoting
glucose uptake into neurons (Bondy and Cheng, 2004). This
corresponds to studies demonstrating increased glucose
utilization in areas of higher IGF1 and IGF1R expression
in the developing brain, and reduced glucose utilization in
IGF1 null brains (Cheng et al., 2000). This pathway also leads to
inactivation of FOXO1, preventing FOXO-driven transcription
of pro-apoptopic genes (Yin et al., 2013). Hence, PI3K signaling
directly inhibits the pro-apoptopic machinery via multiple
pathways.
IGF1R also phosphorylates the Sch protein, which
recruits the GDP2/SOS complex, leading to activation of
Ras, thereby triggering the MAP kinase pathway central
to growth-related gene transcription and mitogenesis
(Figure 1).
IGF1-SIGNALING, AGING AND LIFESPAN
IN MODEL ORGANISMS
IGF1 signaling is central to pathways that promote cell
growth and survival, maturation and proliferation, allowing
for tissue growth and renewal. Furthermore, the activity of
the GH-IGF1 somatotrophic axis decreases with age, and is
almost undetectable in people over 60 years (Junnila et al.,
2013). This has led to many theories that upregulation of
the GH/IGF1 pathway may delay aging. However, studies
of IGF1 signaling on nematodes and many other species
have suggested that, on the contrary, downregulation of
IGF1 signaling delays aging and increases lifespan.
The IGF1 signaling pathway is an evolutionarily ancient
pathway, conserved from C. elegans through to modern humans.
The C. elegans IR-IGF1 receptor homolog is Daf-2. Mutations
that lower the level of Daf-2 double the lifespan of the
C. elegans model (Kenyon et al., 1993). Exactly how Daf-2
mutations increase C. elegans lifespan in unclear. Some daf-2
mutants adopt a quiescent state of reduced movement and
fertility known as the dauer state, whereas other mutants are
shown to have a lower metabolic rate, and other mutants
again demonstrate a metabolic shift to fat production. However,
these findings are not consistent among all daf-2 mutants,
and can therefore not be coupled to lifespan extension
(Kenyon, 2010). Another theory is that daf-2 mutants are
better able to withstand oxidative stress (Holzenberger et al.,
2003). Reduced Daf-2 activity downregulates Akt-mediated
inhibition of Daf-16 (FOXO homolog), allowing Daf-16
translocation to the nucleus for target gene activation. The
transcriptional targets of Daf-16/FOXO may be at least in part
responsible for the stress resistance and longevity associated
with Daf-2 mutants (Lin et al., 1997; Gami and Wolkow,
2006).
The impact of altered Daf-2 activity on lifespan varies
between different cell lineages. While present in ectodermal,
mesodermal and endodermal lineages, it is reduction in
ectodermal (neuronal, skin tissue) daf-2 activity that induces
a dauer state (Guarente and Kenyon, 2000). Restoration of
insulin-like signaling alone in Daf-2 mutants reverts these
mutants back to a wild-type lifespan, whereas restoration of
insulin-like signaling in muscle or adipose tissue had no effect
on lifespan (Wolkow et al., 2000). This study provides persuasive
evidence that insulin/IGF1 signaling in neurons regulates
lifespan. Interestingly, reduction in sensory input to the olfactory
system by mutations in sensory cilia or olfactory support cell
ablation can increase lifespan by up to 50% without affecting
development or reproduction. This suggests that sensory neurons
influence lifespan and this is at least partly mediated through
Daf-2 signaling (Apfeld and Kenyon, 1999). Downstream of
Daf-2 (IGF1R), mutations in age-1 (PI3K homolog) also increase
lifespan, suggesting that reduction in factors downstream of
IGF1 signaling are sufficient to extend lifespan (Morris et al.,
1996).
The effect on lifespan by inhibition of insulin/IGF1 signaling
observed in the C. elegans model is conserved in other species,
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FIGURE 1 | A schematic of Insulin-like growth factor 1 (IGF1) molecular pathways activated in brain maturation and aging. Black rows indicate inhibition,
red rows indicate activation. The underlined proteins have been identified to be genetically associated to aging.
including the Drosophila fly, whereby inhibiting IGF1 signaling
or increasing the activity of FOXO (the Daf-16 homolog) in
adipose tissue increases lifespan (Kenyon, 2010). Heterozygous
mutation of the insulin receptor (IR) in Drosophila extends
lifespan by up to 85% (Tatar et al., 2001). Furthermore,
mutation of CHICO, the IRS homolog, extends lifespan by
48% in homozygotes and 36% in heterozygotes (Clancy et al.,
2001). A striking inverse correlation between IGF1 levels
and lifespan is also observed in mice (Kenyon, 2010). While
IGF1R null mice die shortly after birth (Liu et al., 1993),
heterozygous knockout (KO) of IGF1R extends lifespan by
26% compared to wild-type littermates (Holzenberger et al.,
2003). This mouse model of reduced IGF1 signaling were
normal in size, and displayed normal energy metabolism, but
showed greater resistance to oxidative stress (Holzenberger et al.,
2003).
Interestingly, this is in contrast to mice with IR or IRS KO,
which show severe insulin resistance and die earlier due to
hyperglycemia. From invertebrates to mammals, IGF1 signaling
and insulin signaling became distinct cellular pathways with
different downstream effects. Therefore, IGF1 signaling in
mammals can be manipulated without interfering with systemic
glucose metabolism.
In humans, lowered IGF signaling is also shown to improve
longevity. Mutations known to impair IGFR function are
observed in Ashkenazi Jewish centenarians (Suh et al., 2008).
Additionally, Akt, FOXO3A and FOXO1A mutations are linked
to longevity in numerous patient cohorts (Willcox et al., 2008;
Flachsbart et al., 2009; Kenyon, 2010).
The findings that reductions in Daf-2/IGF1R signaling can
radically increase lifespan would suggest that IGF1 signaling
is directly linked to the aging of organisms, which is in
contradiction to the theory that a fall in the activity of GH-IGF1
somatotropic axis underlies the mechanism of aging.
Although in the whole organism a general decrease of
IGF signaling delays aging, this review will focus on the role
of IGF1 signaling in the developing and aging brain, where
IGF1 signaling in the brain promotes development and, in
some cases, appears to attenuate age-related changes. Numerous
studies outlined below demonstrate the neurotrophic effects of
IGF1 signaling, giving evidence for promotion of neurogenesis,
development and maturation, myelination, prolonged survival
and resistance to injury.
IGF1 AND THE DEVELOPING BRAIN:
EXPRESSION PATTERNS OF IGF1 AND
IGF1R IN THE DEVELOPING BRAIN
IGF1 is produced by all major cell types in the CNS.
IGF1 expression peaks perinatally and falls throughout life,
though it persists in discrete brain regions associated with
continual renewal and remodeling. This is in contrast to
the IGF1 receptor, which is shown to be widely expressed
throughout the brain, and concentrated in neuron-rich areas
including the granule cell layers of olfactory bulb, dentate
gyrus and cerebellar cortex, with little hybridization in white
matter regions (Bondy et al., 1992a). IGF1R is expressed in
all neuroepithelial cell types, and shows a relatively stable
pattern of expression from early development to maturity
(Bondy et al., 1992b). There is, however, a period of increased
IGF1R expression coinciding with increased IGF1 expression
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in specific sensory and cerebellar projecting neurons during
late post-natal development (Bondy et al., 1992b). Early
post-natal IGF1 expression was identified in brain regions where
neurogenesis persisted after birth, including the cerebellum,
olfactory bulb and hippocampus, and was shown to fall after this
period of neuronal proliferation (Bach et al., 1991; Bartlett et al.,
1991).
IGF1 expression persists in these areas in adult brains, but at
levels much lower than that of early neonatal animals (García-
Segura et al., 1991). These expression patterns highlight the
association between regions of increased neurogenesis and local
IGF1 and IGF1R expression during early development.
While local IGF1 expression falls shortly after birth, there
exists throughout life an active transport mechanism that allows
peripheral circulating IGF1 to cross the blood brain barrier
(Fernandez and Torres-Alemán, 2012). This finding, combined
with the fact that IGF1 receptor expression in the brain
persists throughout life, suggests a role for peripherally produced
IGF1 in adult brain function. Therefore, while locally produced
IGF1 appears to play a role in brain function during prenatal and
early post-natal development, peripherally produced IGF1 may
have a continued role in the adult brain.
IGF1 AND THE DEVELOPING BRAIN:
EVIDENCE FROM IN VITRO AND IN VIVO
STUDIES ON THE EFFECT OF IGF1 ON
BRAIN SIZE, NEURONAL CELL NUMBER,
AXONAL GROWTH AND MYELINATION
DURING EARLY DEVELOPMENT
IGF1 has been shown to have pleiotropic actions in all
neural cells, including neurons, oligodendrocytes and astrocytes,
by increasing cell number and promoting maturation and
myelination. This has been proven through in vitro culture
studies, and through both overexpression and under-expression
studies in transgenic mice.
IGF1 and the Developing Brain: Effects of
IGF1 on Neural Stem Cells
In vitro studies examining the effect of IGF1 in neural stem
cells report increased neural progenitor cell proliferation and
maintenance in cell culture following treatment with IGF1
(Drago et al., 1990; Supeno et al., 2013). IGF1 was found to be
more potent than insulin in stimulating mitosis of sympathetic
neuroblasts (DiCicco-Bloom and Black, 1988). Furthermore,
numbers of neurons produced from neural stem cell clones
was increased following administration of IGF1 or heparin or
withdrawal of FGF2 from cell culture, the effects of which
were negated by administration of IGF1 and IGF1BP antibodies
(Brooker et al., 2000). Examination of adult rat hippocampal
progenitor cells showed uniform IGF1R expression, and the
combined addition of IGF1 and FGF2 to these cells in
culture increased DNA synthesis and cell division, without
significant changes in the rate of cell death (Åberg et al.,
2003).
IGF1 and the Developing Brain: Evidence
from Prenatal Overexpression and
Underexpression Studies
Popken et al. (2004) demonstrated through nestin-driven
overexpression of IGF1 early in the embryonic development of
transgenic mice a 6% increase in brain weight by embryonic
day 16, associated with a cortical plate volume 42% greater and
a total cell number 54% greater in the transgenic mice compared
to controls. This increase in total cell number was attributed
to a 15% increase in proliferating cells in the ventricular and
subventricular zones of the embryonic cerebral cortex, which
give rise to the neuronal and glial cell types respectively. At
post-natal day 12, a 27% increase in overall brain weight was
observed, with significant increases in volume and total cell
number in certain brain regions including the cerebral cortex,
subcortical white matter, caudate-putamen, hippocampus,
dentate gyrus and habernacular complex (Popken et al., 2004).
This enhancement in neuroepithelial cell proliferation by
IGF1 during embryonic neurogenesis has been shown to
result from acceleration through the cell cycle (Hodge et al.,
2004). Further studies in the same mouse model reported that,
in ddition to enhanced proliferation of neural progenitors,
there are reduced numbers of apoptopic cells throughout
the cerebral cortex both prenatally and post-natally in the
mice showing IGF1 overexpression, correlating with overall
increased brain weight 9 months post-natally (Hodge et al.,
2007).
Conversely, examination of homozygous IGF−/− KO mice at
2 months demonstrates a grossly structurally normal brain, but
a 38% reduction in brain weight. A reduction in parvalbumin-
containing neurons in the hippocampus and striatumwas shown,
as well as a significant reduction in the thickness of the dentate
gyrus granule cell layer (Beck et al., 1995). IGF1−/− mice also
show reduced dendritic length and complexity, and a 16%
reduction in synaptotagmin levels, suggesting a reduction in
the number of synapses, in the frontoparietal cortex (Cheng
et al., 2003). A study by Liu et al. (2009) showed that brain-
specific IGF1R heterozygous KO mice had brain weights 56%
lower than controls at birth and 60% lower at post-natal day
90. The hippocampus was particularly affected, where the rate
of growth post-natally was much lower in IGF1R heterozygous
KOs compared to wild-type controls, with a greater fall in
the numbers of neurons in the CA1–3 region and a smaller
rise in the neuronal cell number in the dentate gyrus post-
natally. This was attributed to a higher rate of cell death in
IGF1R heterozygous KOmice. In all experiments performed, the
phenotype was more severe in the two IGF1R homozygous KO
mice that survived to adulthood, suggesting that degree of brain
growth retardation was related to the level of IGF1R expression
(Liu et al., 2009).
IGF1 and the Developing Brain: Evidence
from Post-Natal Overexpression and
Underexpression Studies
While the above studies examined the downstream effect of
prenatal IGF1 over-and under-expression on subsequent brain
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development, other studies had focused on the role of IGF1 in
the post-natal period, given that IGF1 mRNA expression in the
developing rodent brain peaks in the first two post-natal weeks
of life. Using a line of transgenic mice that begin to express
the transgene at birth, causing brain-restricted overexpression
of IGF1, studies have shown that IGF1 overexpression causes
increases in brain weight after day 10, with enlargement of
the brainstem, cerebellum, cerebral cortex and hippocampus
(Ye et al., 1996; Dentremont et al., 1999; O’Kusky et al., 2000).
Cerebellar weight was increased by 90%, with concomitant
increases in granule and Purkinje cell numbers by 82% and 20%
respectively (Ye et al., 1996).
Specifically, given the persistence of IGF1 expression in
the hippocampal subventricular zone and dentate gyrus post-
natally, the in vivo actions of IGF1 on growth and development
of the hippocampal dentate gyrus up to 130 post-natal days
have been investigated. Transgenic IGF1 overexpression
was shown to increase granule cell layer and molecular cell
layer by 27%–69%, total number of neurons by 29%–61%,
and total number of synapses in the molecular layer by
42%–105% compared to control littermates (O’Kusky
et al., 2000). Increased neuronal numbers in the dentate
gyrus in the post-natal period is thought to be due not
only to increased neurogenesis but also reduced neuronal
death.
Numerous studies have reported that IGF1 promotes cell
survival in the post-natal brain. Transgenic mice overexpressing
IGF1 have significantly fewer apoptopic cerebellar neurons at
post-natal day 7 compared to wild-type controls, with increased
expression of anti-apoptopic proteins and reduced expression
of pro-apoptopic proteins (Chrysis et al., 2001). Similarly, in
the dentate gyrus of post-natal brains, IGF1 null mice had
higher rates of granule cell proliferation but lower numbers of
mature granule cells, suggesting the IGF1 promotes survival of
granule cells in the post-natal period (Cheng et al., 2001). For a
focused review on the function of IGF1 in brain development and
plasticity see Dyer et al. (2016). The role of IGF1 in improving
neuronal survival and reorganization following injury in both
the developing and aging brain are outlined further on in this
article.
IGF1 and the Developing Brain:
Oligodendrocyte Development and
Myelination
In addition to the effect of IGF1 on neuronal proliferation and
survival in the developing brain, the effect on glial cells, especially
oligodendrocytes, has been investigated through in vitro and
in vivo studies.
In vitro studies show that administration of IGF1 to
oligodendrocyte cells in culture promotes oligodendrocyte
proliferation, differentiation, myelin production and survival
(McMorris and Dubois-Dalcq, 1988; Mozell and McMorris,
1991; Barres et al., 1992; Ye and D’Ercole, 1999).
In vivo studies comparing transgenic mice with increased
IGF-1 expression to those with IGFBP-1 expression (an inhibitor
of IGF1) have shown that the mice with increased IGF-1
expression demonstrate higher numbers of oligodendrocytes,
increased percentage of myelinated axons and increased
thickness of myelin sheath compared to the transgenic mice with
increased IGFBP-1 expression (Ye et al., 1995). In another study,
prenatal overexpression of IGF1 in transgenic mice produced a
mouse brain 55% larger, owing to an overall increase in total
cell number, and a total myelin brain content 130% higher than
that found in their non-transgenic littermates, which was not
associated with a higher percentage increase in oligodendrocyte
number, suggesting that increased meylin content was due to
increased myelin production per oligodendrocyte (Carson et al.,
1993).
Conversely, examination of IGF1 KO mice reported reduced
cerebral and spinal cord white matter volume due to fewer
myelinated axons and oligodendrocytes at post-natal day 55
(Beck et al., 1995). Further detailed study of IGF-1 KO mice
showed consistently reduced overall brain weight 1 week
post-natally compared to wild-type littermates, affecting all
brain regions, as well as reduced myelination in all brain
regions during the first 3 weeks of life, though this normalized
and became similar to that of wild-type mice thereafter. Ths
coincided with reduced levels of myelin-binding protein (MPB)
and proteolipid protein (PLP) in IGF-1 KO mice during the
first 3 weeks, which also normalized and became similar
to controls by 10 weeks, while percentage oligodendrocyte
number was persistently reduced in IGF-1 KO mice at weeks
1, 3 and 10. Additionally, reduced levels of the median subunit
of neurofilament (a neuron-specific intermediate filament which
acts a s a marker of axon growth) was reduced in IGF-1 KO
mice and did not recover as the brain matured (Ye et al.,
2002).
These studies suggest the importance of prenatal
IGF1 expression in the developing brain for axon growth
and CNS myelination in the early post-natal brain.
IGF1 AND THE DEVELOPING BRAIN:
EVIDENCE FROM STUDIES OF EXTERNAL
STIMULI KNOWN TO PROMOTE
PAST-NATAL CORTICAL MATURATION
Certain external stimuli have been shown to promote
neurodevelopment, and in many cases these studies show
that the effect is mediated by IGF1 signaling. In particular, the
visual cortex is studied in the context of how brain development
is affected by external sensory input. For instance, environmental
enrichment (EE), defined as ‘‘a complex of inanimate and social
stimulation,’’ is known to promote hippocampal neurogenesis
and increase dendritic branching and synaptogenesis. It
accelerates development of the visual cortex, causing enhanced
visual acuity and increased expression of BDNF, which is known
to act through the GABAergic system to promote neuroplasticity
(Cancedda et al., 2004). A further study showed that this effect
of EE on post-natal visual cortical development is inhibited by
treatment of enriched pups with IGF1 antagonists and mimicked
by treatment of non-EE pups with IGF1 infusion (Ciucci et al.,
2007). Similarly, maturation of the visual system in preterm
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infants was accelerated by massage therapy, as evidenced both
through electrophysoiogical studies and through visual acuity
testing performed 3 months later. This correlated with higher
serum levels of IGF1 and IGFBP3 in massaged infants. This
was similarly shown in rat pups undergoing tactile stimulation,
who showed faster maturation of electrophysiological tracings
and higher levels of IGF1 in the brain compared to controls
(Guzzetta et al., 2009).
While the above studies use the EE model to investigate the
role of IGF1 in post-natal cortical maturation, other studies have
used the model of monocular deprivation (MD) to assess the role
of IGF1 in neuroplasticity and reorganization, whereby blocking
visual input from one eye leads to structural organization of
the visual cortex, allowing for ocular dominance of the intact
eye. Expression of regulatory IGFBP5 gene is highly upregulated
after MD, and the effects of MD on ocular dominance plasticity
are negated by exogenous application of IGF1 (Tropea et al.,
2006). Given that the capacity of ocular dominance plasticity in
response to short deprivation is a marker of circuit immaturity,
this study further supports the theory that IGF1 signaling
promotes brain maturation in juvenile animals.
IGF1 AND THE ADULT BRAIN: ADULT
NEUROGENESIS
As well as the role of IGF1 in early brain development, much
research has been done into the role of IGF1 in ongoing
neurogenesis and CNS plasticity in the adult brain. In most
regions of the brain, neurogenesis ceases after birth. IGF1 mRNA
expression correlates both temporally and spatially with these
periods of rapid neurogenesis in the perinatal brain. Similarly,
there are certain brain regions, namely the dentate gyrus and
subventricular zone of the hippocampus, where neurogenesis
persists into adulthood, and this correlates with the finding
that IGF1 expression in the brain is diffuse during antenatal
development, but persists only in the subventricular zone and
dentate gyrus of the hippocampus after birth (Anderson et al.,
2002). IGF1 expression levels decrease again later in life, again
at a time that corresponds with a decrease in hippocampal
neurogenesis. Therefore, much research has been done to
investigate how manipulation of IGF1 signaling affects adult
hippocampal neurogenesis.
It has already been noted in in vitro studies that adult
hippocampal neural progenitor cells express IGF1R, and that
administration of IGF1 with FGF2 increased progenitor cell
proliferation (Åberg et al., 2003). This group further suggested
that low-dose IGF1 treatment triggered a small increase in the
differentiation of neuronal progenitors into neurons. A further
in vivo study used hypophysectomied rats, as this model would
have low levels of circulating IGF1. Six days of peripheral
subcutaneous IGF1 administration increased proliferation of
neuronal progenitors in the hippocampal dentate gyrus, as
evidenced by BrdU uptake. After 20 days of subcutaneous
IGF1 administration, these new cells expressed neuronal-specific
proteins, suggesting stimulation of neurogenesis (Aberg et al.,
2000). This suggests that, while local IGF1 mRNA expression
levels fall after birth, peripheral IGF1 plays a role in adult
hippocampal neurogenesis.
Another study looked at the effect of local
IGF1 administration on neuronal cell numbers in the dentate
gyrus. Mice aged 5, 18 and 28 months were examined. The
dentate gyrus was divided for analysis into the proliferative
subgranular zone (PZ), the granular cell layer (GCL) and the
hilus, and the numbers of new cells were quantified using BrdU
labeling. This study showed that the number of BrdU labeled
cells decreases with age, with 80% fewer BrdU labeled cells in
the PZ of the 18 month old rats than the 5 month old rats, with
a much smaller but significant decrease in BrdU labeled cells in
the hilus, though no age-related changes were observed in the
GCL. Intracerebroventricular infusion of IGF-I maintained an
approximately three-fold increase in the number of BrdU-labeled
cells in the PZ, GCL and hilus in old rats examined 31 days after
BrdU injection. IGF-I did not, however, selectively induce a
neuronal fate since the percentage of BrdU-labeled cells in
IGF-I-treated animals that colocalized NeuN was identical to
that observed in age-matched controls (Lichtenwalder et al.,
2001). Transgenic overexpression of IGF1 was similarly shown to
increase the proliferation of neural stem cells in the subgranular
and subventricular zones of adult mice brains (Yuan et al.,
2015). In this study, however, IGF1 overexpression also led
to an increase in the differentiation of neuronal stem cells
into neurons, in contrast to the previous study (Yuan et al.,
2015).
A recent study has looked in detail at the effects of both
global and brain-specific KO of IGF1 in adult hippocampal
neurogenesis. Global IGF1 KO mice had both low brain
IGF1 expression and low serum IGF1 levels, and showed
a 2.4-fold reduction in hippocampal volume compared to
controls. Using extensive immunohistochemisty studies, this
group demonstrated higher staining for markers of immature
differentiation from neural progenitor cells to neurons in IGF−/−
mice compared to controls, reduced staining for markers of
the later stages of differentiation, and disorganized staining
for markers of differentiated granule cells in the GCL of the
dentate gyrus compared to controls (Nieto-Estévez et al., 2016b).
IGF1−/− cells in the GCL showed greater proliferative capacity
but more immature morphology compared to controls (Nieto-
Estévez et al., 2016b). The group then studied the effects of brain-
specific IGF1 KO on adult hippocampal neurogenesis. These
mice had normal body size and total brain volume compared to
controls, but reduced volume of the GCL of the dentate gyrus. As
with the global IGF1 KO mice, these mice demonstrated greater
immunostaining for immature differentiation markers and more
disorganized distribution of mature differentiation markers in
the GCL of the dentate gyrus (Nieto-Estévez et al., 2016b). In
all, this study of two IGF1−/− mouse models demonstrates that
a lack of IGF1 in the brain is associated with accumulation
of neuronal progenitor cells, impaired transition from neural
progenitor to mature granule cell neurons, a reduction in
mature morphology of granule cells and disorganization of
the GCL (Nieto-Estévez et al., 2016b), all of which supports
the idea that IGF1 signaling is key in promoting organized
adult hippocampal neurogenesis. Thus, IGF1 not only promotes
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adult neurogenesis through increased stem cell proliferation,
but also through organized cell migration. This is similarly
demonstrated in the study of IGF1 KO mice who showed
reduced neuroblast migration from the subventricular zone to
the olfactory bulb and poor organization of immature neurons
in the olfactory bulb compared to normal mice (Hurtado-Chong
et al., 2009).
Multiple processes are thought to stimulate adult
neurogenesis, the best studied of which is exercise, and
recent studies show that this effect is mediated through
IGF1 signaling. This was shown through administration of
an antibody that blocked systemic IGF1 uptake into the brain
parenchyma, which reversed the exercise-induced effects on
hippocampal neurogenesis (Trejo et al., 2001). Blocking IGF1R
reverses exercise-induced increases in BDNF, suggesting that
the downstream effects of IGF1 signaling are at least in part
medicated though upregulation of brain-derived neurotrophic
factor (Ding et al., 2006).
Exercise promotes functional recovery of spatial memory
acquisition in rats who have undergone hippocampal injury,
and attenuated the loss of motor coordination in rats following
brainstem injury or Purkinje cell degeneration (Carro et al.,
2001). The neuroprotective effects of exercise demonstrated in
this study were reduced in rats who received subcutaneous
IGF1 antibody treatment (Carro et al., 2001). Memory deficits
are frequently reported in depression, and imaging studies
have shown decreased hippocampal volume in patients with
depression. Antidepressant therapy, including SSRIs and ECT,
is known to cause upregulation of BDNF, and this has recently
been shown to be IGF1-dependent (Chen and Russo-Neustadt,
2007). For a focused review on IGF1 and neurogenesis please see
Nieto-Estévez et al. (2016a).
IGF1 AND THE ADULT BRAIN:
PROLONGED SURVIVAL, REDUCED CELL
DEATH, RESISTANCE TO INJURY,
REPARATION AND NEUROPLASTICITY IN
RESPONSE TO ENVIRONMENTAL CUES
In addition to its role in neurogenesis in the adult brain, IGF1 has
been studied for its effect on CNS reparation and plasticity
using injury and sensory deprivation models. These studies
may indicate that falling levels of IGF1 in the aging brain may
indirectly lead to aging through reduced reparation, remodeling
and resistance to stress.
One model of injury is the cerebellar deafferentiation
model, whereby the olivocerebellar pathway is transected. The
remaining olivocerebellar fibers reinnervate the hemicerebellum,
but only in the early post-natal period (days 7–10). However,
injection of IGF1 into the cerebellum of rats aged 11–30 days
allowed for reinnervation of this pathway, indicating that
this period of neuroplasticity is extended with use of IGF1
(Sherrard and Bower, 2003). IGF1-mediated reinnervation of
the olivocerebellar pathway caused full motor recovery in rats
rendered ataxic after 3-acetylpyridine-induced cerebellar injury
(Fernandez et al., 1998).
More evidence for its role in reparative neuroplasticity
is shown through the use of excitotoxicity models. Chronic
intracerebral administration of IGF1 following an excitotoxic
lesion in the dentate gyrus caused increased dendritic formation
in young neurons in the dentate gyrus compared to untreated
controls, and recovery of contextual fear memory, which is
a dentate gyrus-dependent function (Liquitaya-Montiel et al.,
2012). Another model of dentate gyrus injury is injection of
trimethyltin, which is shown to cause elevated IGF1 mRNA
levels in the hippocampus. Mice deficient in IGF1 had a
significant level of CA1 hippocampal cell death, implying a
role for IGF1 in CA1 hippocampal cell survival (Wine et al.,
2009).
IGF1 is also thought to be protective in hypoxic-ischemic
injury. Intracerebroventricular infusion of IGF1 during perinatal
asphyxia in near-term foetal sheep was linked to reduced loss
of striatal cholinergic and GABAergic neurons compared to
controls on post-mortem examination (Guan et al., 2000). A
single dose of intracerebroventricular IGF1 2 h hypoxic-ischemic
injury reduced somatosensory deficits for up to 20 days after the
initial insult (Guan et al., 2001). The effects of malnourishment in
the post-natal period are also attenuated by IGF1 administration.
Malnourished mice treated with IGF1 comparable brain weights
and cell numbers compared to nourished controls, and higher
numbers of oligodendrocytes and expression of myelin markers
MPB and PLP, suggesting that this protective effect is through
increased myelination (Ye et al., 2000).
The effects of IGF1 signaling following traumatic brain injury
(TBI) have also been studied. Overexpression of IGF1 was
shown to increase the density of hippocampal immature
neurons following TBI. This was shown to be the result of
post-traumatic proliferation and differentiation of neural stem
cells into immature neurons, rather than through protection
against initial insult. IGF1 overexpression also enhanced
dendritic arborization of immature neurons compared to
normal controls (Carlson et al., 2014). Thus, through enhanced
neurogenesis and maturation, IGF1 overexpression accelerated
recovery.
The role of IGF1 in activity-dependent neuroplasticity is
also demonstrated through the use of sensory deprivation
models. MD is a model of reduced activity-dependent activity,
whereby one eye is deprived of visual stimuli, which leads
to neuronal network reorganization with subsequent ocular
dominance of the normal eye. IGFBP-5 is highly upregulated
after MD, and administration of IGF1 promotes recovery
of normal visual function in these models (Tropea et al.,
2006) through upregulation of BDNF (Landi et al., 2009).
Based on these findings, studies were performed to investigate
whether administration of IGF1 in adult brains restores
neuroplasticity. Adult rats underwent MD by eyelid suturing,
and were then treated with IGF1. This was shown to trigger
ocular dominance plasticity compared to MD rats untreated
with IGF1 (Maya-Vetencourt et al., 2012). Furthermore, in
rats rendered amblyopic by long-term sensory deprivation,
those treated with IGF1 prior to restoration of sensory
input showed full recovery of visual acuity compared to
rats untreated with IGF1 (Maya-Vetencourt et al., 2012).
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Downregulation of intracortical inhibitory GABA activity,
increased utilization of glucose, and interaction with 5-HT
were offered as potential mechanisms through which
IGF1 mediates this restoration of plasticity. An alternative
sensory deprivation model is that of hindlimb unloading (HU).
In adult rats, 14 days of HU decreases IGF1 levels in the
somatosensory cortex (Mysoet et al., 2014) and shrinks the
somatotopic representation of the hindpaw. Administration
of IGF1 prevents this change in somatotopic representation
(Papadakis et al., 1996; Mysoet et al., 2015). These interventional
studies have demonstrated that IGF1 administration alters
neuronal plasticity in response to sensory deprivation in adult
animals.
The above studies outline the role of IGF1 in adult
neurogenesis, reparation and reorganization in response to
stressors. It is therefore possible that loss of these IGF1-driven
mechanisms with age leads to age-related cognitive changes.
However, numerous studies outlined later in this article report
the contrary theory that it is a reduction IGF1 signaling that is
neuroprotective following CNS insult.
IGF1 AND THE AGING BRAIN: EVIDENCE
FROM MOLECULAR BIOLOGY
The GH-IGF1 signaling pathway is the best characterized
hormonal pathway in the process of aging. Pulsatile pituitary
secretion of GH in response to stimuli such as induced
hypoglycemia or arginine administration declines with age
(Laron et al., 1969). This is associated with concomitant
declines of circulating IGF1 levels (Johanson and Blizzard,
1981). Numerous age-related changes in the brain have been
identified that suggest changes in IGF1 signaling. The density of
GH receptors decreases with age, while reports are conflicting
regarding age-related changes in IGF1 receptor density, with
one group reporting increased density of IGF1R expression
in the CA3 region of the hippocampus (Chung et al.,
2002) and others reporting reduced decreased hippocampal
and cortical IGF1R density in aging rats (D’Costa et al.,
1993; Sonntag et al., 1999). Expression of IGF1 mRNA
was reported to be reduced in the cerebellum of aging
rats (Pañeda et al., 2003). These findings would suggest
that IGF1 signaling is reduced in the aging brain. How
this is linked to functional changes in the aging brain is
unclear.
IGF1 AND THE AGING BRAIN: EVIDENCE
FROM COGNITIVE TESTING
Therefore, studies have been done to examine whether reduced
IGF1 signaling is linked to cognitive dysfunction. Studies in
humans found a significant correlation between better perceptual
motor performance, information processing speed and fluid
intelligence and higher circulating IGF1 levels (Aleman et al.,
1999, 2001). Others have found a correlation between higher
IGF1 levels and higher MMSE scores (Paolisso et al., 1997;
Rollero et al., 1998). The MMSE is a well-validated test in
terms of repeat-test reliability and tracking of cognitive function
over time. In a 2 year prospective study, higher levels of
circulating IGF1 levels were associated with reduced cognitive
decline over the study period. However, these findings are
inconsistent, with many studies also reporting no correlation
between IGF1 and attention, fluid intelligence, memory or
cognitive decline (Papadakis et al., 1995; Aleman et al., 1999,
2001).
IGF1 AND THE AGING BRAIN: EVIDENCE
FROM INTERVENTIONAL STUDIES
In any case, correlation does not imply causation. Therefore
interventional studies in human were performed to assess
if GH or IGF1 levels improved cognitive function, but
the results were conflicting and ultimately inconclusive
(Papadakis et al., 1996; Friedlander et al., 2001). In mice,
intracerebroventricular infusion of IGF1 attenuated age-related
deficits in working and reference memory as assessed by Morris
water maze and object recognition tasks (Markowska et al.,
1998).
Further work has been done in mice studies to assess the
downstreammolecular effects of IGF1 administration in an aging
brain. Intracerebroventricular infusion of IGF1 has been shown
to increase microvascular density in aged animals (Sonntag et al.,
2000b). Furthermore, it increases hippocampal NMDAR2A/B
subunit expression (Sonntag et al., 2000a), which is relevant
because NMDAR2B subunit ablation has been shown to impair
spatial learning (Clayton et al., 2002). Local IGF1 increases local
glucose utilization in the anterior cingulate cortex of aged rats
(Lynch et al., 2001). Finally administration of IGF1 attenuates the
age-related decline in neurogenesis in aged rats (Lichtenwalder
et al., 2001).
IGF1 AND DISEASE: EVIDENCE FROM
DISORDERS OF NEURODEVELOPMENT
AND NEURODEGENERATION
IGF1 and Disorders of Impaired
Neurodevelopment
In order to better understand the physiological roles of
IGF1 in normal neurodevelopment and aging, one can look
at IGF1 activity in the context of known disorders of
neurodevelopment and neurodegeneration. For instance, Rett
Syndrome is an X-linked neurological disorder characterized by
seemingly normal post-natal development initially, followed by a
sudden deterioration in function, with loss of acquired functional
and motor skills at 12–18 months of age. Rather than being a
neurodegenerative process, the underlying pathology is thought
to be a stagnation in neuronal maturation. It is caused by a
mutation in the MECP2 gene, which codes a transcriptional
modulator. It is abundant in neuronal tissue and its expression
correlates with that of synaptic maturation. A downstream
factor of MECP2 is BDNF, which activates the same PI3K and
MAPK pathways that are activated by IGF1 signaling. Therefore,
subcutaneous injections if IGF1 have been administered to both
mouse models and human subjects to assess if this intervention
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can reverse the Rett Syndrome phenotype. IGF1 has been
shown to increase brain weight, dendritic spine density and
levels of PSD-95, a post-synaptic scaffold protein that promotes
synaptic maturation, in MECP2 null mice, as well as partially
reverse the reduction in amplitude of excitatory post-synaptic
current in MECP2 mice (Tropea et al., 2009). Interestingly,
persistence of ocular dominance plasticity following MD, a
marker of neuronal immaturity, is a feature of MECP2 mouse
models of Rett syndrome. It is prevented by pre-treatment with
IGF1, giving further evidence for the role of IGF1 in neuronal
circuit maturation and reduction in neuroplasticity (Tropea
et al., 2009; Castro et al., 2014). These studies indicate the
role of IGF1 signaling in neuronal circuit maturation. Similarly,
work in SHANK3 deficient models of autism have showed that
treatment with IGF1 promotes maturation of excitatory synapses
(Shcheglovitov et al., 2013), and reverses deficits in LTP, AMPA
signaling and motor function (Bozdagi et al., 2013). Therefore,
through the study of IGF1 in the context of disorders caused by
poor brain development, it appears that IGF1 promotes neuronal
development and brain maturation. For a review focused on
IGF1 function in neurodevelopmental disorders, see Vahdatpour
et al. (2016).
IGF1 and Disorders Associated with Brain
Aging
Findings through the study of IGF1 in age-related
neurodegenerative disorders, however, have been contradictory,
with some studies reporting that reduced IGF1 signaling is
neuroprotective, while others claim that reduced IGF1 signaling
with age contributes to brain aging. For instance, Alzheimer’s
disease (AD) is a neurodegenerative disease associated
with aging, and one group have shown that a reduction in
IGF1 signaling rescues mice from AD-like pathology. An AD
mouse model with reduced IGF1 signaling was created, and was
reported as having reduced neuronal loss and behavioral deficits
compared to the control AD mouse model with normal levels of
IGF1 signaling (Cohen et al., 2009). This was attributed to tighter
aggregation of Aβ plaques leading to reduced proteotoxicity.
These mice also show greater resistance to oxidative stress than
mice with intact IGF1 signaling (Holzenberger et al., 2003),
suggesting that these findings may be due to an enhanced
capacity to protect against the inflammatory effects of Aβ
plaques. Similarly, another group demonstrated protection
of the aging brain from amyloid pathology by knocking out
neuronal IGF1R activity in the brains of adult rats (Gontier et al.,
2015). In this study, IGF1R KO in adult neurons led to reduced
Aβ pathology and neuroinflammation, along with preservation
of spatial memory. Another study reported reduction in Aβ
plaques and improved learning and memory following IRS2 KO
compared to controls in APP transgenic mice (Killick et al.,
2009).
This is in contrast to the prevailing theory that AD is
a disorder of insulin and IGF1 resistance. AD has recently
been termed ‘‘Type 3 Diabetes,’’ given the observation that the
spectrum of Mild Cognitive Impairment—AD is associated with
global reductions in glucose uptake and utilization occurring
early in the course of the disease (Steen et al., 2005; Mosconi
et al., 2013). In particular, hippocampal hypometabolism has
been observed to correlate with faster progression to dementia
(Mosconi et al., 2013). AD could therefore represent a form of
CNS insulin resistance. Expression patterns of IR, IGF1 receptor
(IGF1R), the intracellular substrate proteins IRS1 and IRS2,
and the regulatory IGFBP-2, have been studied in brains
affected by AD. One study reported increased IGF1R and
decreased IGFBP-2 expression in AD brains, with higher IGF1R
expression levels concentrated around amyloid plaques and
in neurons with neurofibrillary tangles. These AD neurons
showed decreased intracellular levels of IRS1 and IRS2, in
association with greater levels of the phosphorylated inactivated
forms of these proteins. These findings would suggest that AD
neurons show resistance to IGF1 signaling (Moloney et al.,
2010). Similarly, another study showed that cerebral neurons
in AD brains demonstrate reduced responses to insulin and
IGF1 signaling, mainly through phosphorylation and subsequent
inactivation of IRS1 (Talbot et al., 2012). Another group
that found that mutant rats with lower circulating levels of
IGF1 have higher levels of Aβ plaques in the brain, and that
levels of Aβ can be reduced in aging rats to levels similar to
that in young rats by increasing serum levels of IGF1 (Carro
et al., 2002). This is thought to be due to increased clearance
of Aβ by albumin and transthyretin carrier proteins due to
increased choroid plexus permeability to these proteins (Carro
et al., 2002). Furthermore, IGF1R blockade in the choroid
plexus worsens AD like pathology, causing amyloidosis, tau
hyperphosphorylation and cognitive disturbance (Carro et al.,
2006). These studies would therefore suggest that decreased
insulin-IGF1 signaling in the brain at least correlates with the
development of AD.
The effect of IGF1 signaling in the pathogenesis of
Huntington’s disease (HD) has also been investigated. This
is a triple repeat disorder caused by mutation of the HTT
protein, whereby elongation of the CAG triple repeat leads
to a resultant HTT protein with a prolonged polyglutamine
tract. This prolongated protein is cut into toxic fragments that
aggregate, causing neurotoxicity and degeneration. Reduced
IGF1 signaling is linked to pathological and symptomalogical
improvements in mouse models of HD. The R6/2 mouse
model of HD showed more rapid neurodegeneration
following increased expression of IRS2, while decreasing
IRS2 expression is associated with a longer lifespan in this
model (Sadagurski et al., 2011). This is attributed to fewer
polyQ-HTT aggregates in the brain. Conversely, another study
showed that treatment of neurons transfected with the HTT
mutation with IGF1 reduced polyQ-htt aggregation through
Akt-mediated huntingtin phosphorylation (Humbert et al.,
2002).
IGF1 AND METABOLISM: TARGETING IGF1
IGF1 signaling has many effects on metabolism, at the tissue and
cellular levels. This signaling is not limited to glucose and lipid
homeostasis but also influences protein turnover (Sharples et al.,
2015).
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Manipulating IGF1 depends on our understanding of the
metabolic trade-offs, especially in the brain, adipose tissue
and skeletal muscle, that are associated with it. IGF and its
related molecules are important in protein metabolism and
the regulation of skeletal muscle mass. KO of IGFI, IGFII or
the IGFI receptor causes neonatal lethality and decreases in
skeletal muscle mass in rodents (Sharples et al., 2015). The
role of IGF1 and its related molecules in the maintenance of
skeletal muscle mass in humans is especially important for
elderly individuals whose IGF1 levels decrease with age and
are at risk of frailty (Maggio et al., 2013) and sarcopenia
(Sharples et al., 2015). Manipulating metabolism by using
dietary restriction offers a similar mechanism to reduced
IGF1 signaling in that it results in the inhibition of mTOR
and it has also been linked to reduced IGF1 levels. It has
the potential to be used in combination with an increase in
protein or amino acid intake to counteract the losses in skeletal
muscle that accompany a reduction in IGF1 (Sharples et al.,
2015).
Choosing which pathway to target poses an obstacle to the
modification of IGF1 signaling. mTOR, which functions through
complexes mTORC1 andmTORC2, might be a promising target.
mTORC1 is responsive to nutrients, energy and growth factors
and its inhibition has been shown to decrease aging rate and
age-related weight gain in mice (Hu and Liu, 2014). KO of
RAPTOR, an mTORC1-specific accessory protein, in adipose
tissue preserves the lifespan extension seen in other models
reducing Insulin/IGF1 signaling while also improving metabolic
markers such as glucose tolerance and insulin sensitivity (Hu
and Liu, 2014). This, taken with the detrimental effects of
KO on tissues such as skeletal muscle and the importance
of IGF1 in metabolism in the developing brain, suggests that
tissue-specific reductions in signaling may be one way of
overcoming this obstacle. In addition to approaches which
take into account specific pathways and tissues, it may also
be beneficial to investigate the differences in the effects of
IGF1 reductions at different time points. Human population
studies point to a positive impact of IGF1 reductions at a
young age and elevations at an old age (Sharples et al.,
2015).
It has been questioned whether the extended longevity
afforded by reduced IGF-1 signaling and its effects on
metabolism are mediated in the same way. In fact, it has
recently been suggested that extended lifespan in the Ames
and Snell dwarf mice is not due to IGF1 levels but rather the
decrease in GH (Brown-Borg and Bartke, 2012). Furthermore,
it is thought that distinct sets of neurons mediate the
functions of insulin/IGF1 in the brain. KO of IRS2 in the
entire brain in mice does result in lifespan extension but at
22 months these mice are also overweight, hyperinsulinemic
and glucose-intolerant, demonstrating the centrality of this
pathway in metabolic homeostasis. Nutrient-sensing which is
central to the regulation of glucose and lipid homeostasis
is carried out by the leptin-sensitive neurons of the arcuate
nucleus which contain IRS2 and the IR. While it is in these
neurons that insulin/IGF1 exert profound effects on metabolism,
IRS2 is not required for leptin action. So then, IRS2 in
these neurons mediates the functions of insulin/IGF1 ad not
those of leptin, once again highlighting the importance of
insulin-like signaling in metabolism. Interestingly, the decrease
of IRS2 on leptin receptor-expressing neurons did not result in
the increase in lifespan seen with overall IRS2 decrease. These
results indicate that the neurons which act as the metabolic
mediators of insulin/IGF1 signaling in the CNS are distinct
from those which underlie mammalian lifespan extension
due to a reduction in insulin/IGF1 signaling (Sadagurski
and White, 2013; White, 2014). This provides a powerful
starting point for the potential development of strategies
to manipulate IGF1 function without causing metabolic
dysfunction.
There is a paradox presented by the Insulin/IGF1 signaling
pathway in metabolism which warrants further research. In the
CNS, this paradox could well be due to the existence of neuronal
subsets which mediate the effects of IGF1/Insulin and in the
periphery could be owed to the differing actions of IGF1 on
various tissues. The importance of IGF1 and its related molecules
on metabolism is undeniable and if manipulated correctly could
prove to be viable therapeutically.
THE DEBATE CONTINUES
In conclusion, the above studies largely support a role for
IGF1 signaling in brain development, and adult neuroplasticity
and neurogenesis. However, while numerous studies report
that IGF1 signaling serves to delay brain aging, and that the
known fall in IGF1 signaling with age acts as a causative
factor in age-related brain changes, there remain as many
studies that stand in contradiction, and suggest that a
reduction in IGF1 signaling delays age-related changes and
diseases.
IGF1 levels are higher in the developing brain, and this is
shown, through the studies outlined above, to promote neuronal
development. It activates the PI3K pathway, which promotes
survival by directly inactivating pro-apoptopic machinery (van
der Heide et al., 2006), and increases glucose uptake by
neurons (Bondy and Cheng, 2004). Post-natally, IGF1 promotes
neuronal maturation, and has been shown to partially correct
the phenotype of certain neurodevelopmental disorders. IGF1 is
associated, in the adult brain, with regions of continued
neurogenesis. These findings would suggest that IGF1 signaling
exerts an overall neuroprotective effect, and that falling
IGF1 levels with age contribute to the effects of aging in the
brain.
However, there also exists a body of evidence suggesting that
reduced IGF1 signaling attenuates the effects of aging, both in the
brain and in the whole organism. A reduction in IGF1 signaling
increases the life span of C. elegans, as DAF-2 mutants with
a lower level of DAF-2 signaling have a lifespan double that
of normal controls (Kenyon et al., 1993). With regards to
brain function, age-related decline in axonal regeneration in
C.elegans was shown to be regulated by DAF-2 signaling. While
the rate of axonal regeneration following injury was 65% in
day1 C.elegans worms and 28% in day 5 worms, the same
experiment in DAF2−/− worms had no reduction in axonal
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degeneration. Reduced DAF-2 signaling allowed for increased
DAF-16 activity, stimulating neuronal regeneration in response
to injury (Byrne et al., 2014). However, in the C. elegans, the
insulin and IGF1 pathways are not diverged, and therefore
the effects of IGF1 on aging cannot be studied in isolation.
Studies of IGF1 signaling and lifespan in mammals have also
been done, and an IGF1R+/− transgenic mouse model with a
reduced level of IGF1 signaling activity has been created that has
a longer lifespan than control mice, and demonstrated greater
resistance to oxidative stress (Holzenberger et al., 2003). These
findings would therefore suggest that the fall in IGF1 signaling
with age is not in fact the cause of aging, but is perhaps a
protective mechanism that occurs as to attenuate the effects of
aging.
These contradictions may arise partly because of the
differential activity of IGF1 signaling in the brain compared
to the whole body in different experimental models. One
particular study characterizes the distinction in Ames mice,
which have a primary deficiency in GH, leading to low levels
of circulating IGF1. These mice demonstrate a longer lifespan,
which has been attributed to absence of GH-IGF1 signaling,
thereby affording evidence that IGF1 signaling contributes to
aging. However, Sun et al. (2005) demonstrated that while these
Ames mice show lower levels of GH and IGF1 peripherally,
they have elevated levels of IGF1 in the hippocampus compared
to normal mice. Furthermore, this correlated with higher
levels of neurogenesis in the dentate gyrus, compared to the
controls (Sun et al., 2005). This elevated level of neurogenesis
in the Ames mice may underlie the observation that these
mice showed less age-related cognitive deficits. Therefore,
while globally reduced IGF1 signaling appears to extend the
lifespan of these organisms, one should not assume that
brain-specific IGF1 signaling is also reduced, or that the
effect of IGF1 activity in the brain compared to the rest
of the organism on the process of aging is necessarily the
same.
Contradictions again arise when studying the neuroprotective
effect of IGF1 signaling in hypoxic-ischemic injury. While
above studies describe reduced neuronal loss following
intracerebroventricular infusion of IGF1 (see above), other
studies report that following Cre-LoxP-mediated inactivation
of IGF1R in forebrain neurons, there was reduced neuronal
damage, inflammation and edema in response to hypoxic-
ischemic insult (De Maghalaes Filho et al., 2016).
These contradictions between different studies may be due to
the different approaches taken: decreasing IGF1 or the receptor,
or the IRS receptor, or the targeting of the modulators IGFBPs.
In fact, the systems are highly regulated and the changes in
each factor may have a different effect. For example, a moderate
decrease in IGF1R increases life span, contrary to what happens
to decreases in IGF1. Another factor to take into account is
the integration insulin-IGF1 in the brain. In neurons, IRSBPs
proteins and IGF1R form a complex which also binds insulin
and may activate different intracellular signals. This interaction
should be taken into account in therapies which use IGF1 to
improve brain function, because the variability of the results may
be due to different levels of insulin in the body. This theory is
in line with the homeostatic function of IGF1 as a connector
between body and brain. In addition, as demonstrated by Sun
et al. (2005), inconsistencies also arise when the differential
activity and effect of IGF1 in different organ systems is not taken
into account, for it may be the case that peripheral and brain
IGF1 signaling have opposing effects, with the former leading
to overall acceleration of aging in the body while the latter
continues to promote renewal and reparation. Furthermore,
it is possible that while IGF1 signaling continues to promote
neuronal development and plasticity throughout life, through
its effects on cellular apoptotic machinery, glucose utilization
and other neurotrophic factors, such anabolic process may
simultaneously contribute to aging through accumulation of
reactive oxygen species and resultant prolonged oxidative stress
over time.
In all, there remains much to be done in elucidating
the role of IGF1 signaling in the brain as it develops,
matures and ages. IGF1 appears to act in concert with BDNF
and other neurotrophic factors to promote neurogenesis and
remodeling in the brain. However, its overall effects on energy
metabolism and cellular oxidation may contribute to aging
in all organs. What is obvious is that it is not simply
a matter of high IGF1 signaling early in life promoting
development and falling levels thereafter underlying the process
of aging. An evolutionarily ancient pathway, IGF1 signaling has
likely taken on numerous differential roles in different body
tissues in health and disease (Forbes, 2016), and its complex
effects on cellular maturation, tissue development and energy
metabolism may contribute to organismal development and
aging simultaneously.
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